Synaptogenix Inc (NASDAQ: SNPX) announced a peer-reviewed paper published in the Frontiers Aging Neuroscience. The paper came from a collaboration between the company’s Chief Science Officer and President, David Alkon, M.D., and a lead researcher from the Thomas Jefferson University, Jarin Hongpaisan, M.D.
According to Dr. Alkon, having the journal publish the results on the efficacy of Bryostatin is an honor. He adds that the study made them realize that patients with Alzheimer’s disease had vascular microvessel deficiencies.
The company used the drug on mice with Alzheimer’s disease
The researchers realized that mice with Alzheimer’s disease had a similar deficiency. They then used Bryostatin to treat them. The treatment stopped the decline of the microvessels and also created new ones. Because of these results, the company could proceed to a Phase IIb study of the drug, which is continuing.
George Perry from Synaptogenix adds that Bryostatin offers oxidative and vascular valves to clients with Alzheimer’s disease. For this reason, the therapy could help cure propel with the disease. Perry, who has done a lot studies on oxidative stress caused by Alzheimer’s disease, is excited by the ability of Bryostatin to reverse the disease.
Synaptogenix, pharmaceutical company, focuses on creating life-changing therapies for people with developmental and neurodegenerative disorders. One of its top candidates, Bryostatin-1, is for patients with moderate to severe Alzheimer’s disease.
The drug might also treat Fragile X syndrome
The company has also found that Bryostatin-1 could potentially reverse Fragile X syndrome. This disorder is very rare and has limited treatment options. If Bryostatin-1 proves effective for treating the disorder, it could serve an area of high unmet need.
For this reason, the FDA has given Bryostatin Orphan Drug Designation to treat Fragile X syndrome. This designation is for therapies that have the potential to treat diseases of high unmet needs. It gives pharmaceutical companies the incentive to develop drugs for rare diseases. These incentives include additional years for exclusive marketing to help the company benefit more from its development.
The company also believes that the therapy could treat traumatic brain injury and multiple sclerosis. So far, the company has tested Bryostatin for over 15000 cancer patients.
